Ovid Therapeutics Inc.
OVID
$1.22
$0.087.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.65M | 548.00K | 566.00K | 632.00K | 568.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.65M | 548.00K | 566.00K | 632.00K | 568.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 6.65M | 548.00K | 566.00K | 632.00K | 568.00K |
| SG&A Expenses | 23.22M | 26.44M | 27.59M | 27.00M | 28.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.42M | 57.76M | 62.65M | 68.28M | 67.02M |
| Operating Income | -41.77M | -57.22M | -62.08M | -67.65M | -66.45M |
| Income Before Tax | -38.18M | -24.97M | -26.43M | -32.50M | -29.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.18 | -24.97 | -26.43 | -32.50 | -29.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.18M | -24.97M | -26.43M | -32.50M | -29.75M |
| EBIT | -41.77M | -57.22M | -62.08M | -67.65M | -66.45M |
| EBITDA | -41.20M | -56.60M | -61.47M | -67.06M | -65.88M |
| EPS Basic | -0.53 | -0.34 | -0.37 | -0.45 | -0.41 |
| Normalized Basic EPS | -0.35 | -0.24 | -0.28 | -0.33 | -0.31 |
| EPS Diluted | -0.53 | -0.35 | -0.37 | -0.46 | -0.42 |
| Normalized Diluted EPS | -0.35 | -0.24 | -0.28 | -0.33 | -0.31 |
| Average Basic Shares Outstanding | 284.14M | 283.95M | 283.62M | 283.30M | 282.94M |
| Average Diluted Shares Outstanding | 284.14M | 284.23M | 283.90M | 283.58M | 283.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |